Cybin (NEO: CYBN) (NYSE American: CYBN) ‘One Step Closer’ to Creating Best Therapy for Mental Health

November 19, 2021 11:35:59
  • Company releases positive results from preclinical study focusing on psilocybin program CYB003
  • Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare
  • Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration
According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) ( This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs ( “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare, but few companies have addressed the well-known limitations and side effects of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW) San Francisco, California 415.949.5050 Office PsychedelicNewsWire is part of the InvestorBrandNetwork